Floatz logo

DALPICICLIB ISETIONATE

HCC

Sun Yat-sen UniversitySmall moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the HCC cohort.

Asset / SponsorPhaseRating
CARVEDILOL
Tongji Hospital
Phase 4BB
EOB-DTPA
Charite University, Berlin, Germany
Phase 4BB
Hepcortespenlisimut-L
Immunitor LLC
Phase 3B
Tirelizumab
Chen Xiaoping
Phase 4B
ASCRINVACUMAB
Suzhou Kintor Pharmaceutical Inc,
Phase 2B

View all 39 →

Same molecule, other indications

DALPICICLIB ISETIONATE is also rated in:

Breast CancerDormant
BB
Indicative ·
66 / 100
View asset →
Triple Negative Breast Cancer (TNBC)Dormant
B
Indicative ·
63 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →